

HLA-A\*11:01&amp;B2M&amp;KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His &amp; Avi),

**General Information**

Synonyms:	MHC;K-Ras 2;NS;K-RAS4A;KRAS;NS3;KI-RAS;K-RAS2A;K-RAS2B;RALD;C-K-RAS;RASK2;CFC2;KRAS2;K-RAS4B;KRAS1;GTPase Kras
Protein Construction:	Gly25-Thr305 (HLA-A*11:01), Ile21-Met119 (B2M) and VVVGADGVGK peptide
Species:	Human
Expression Host:	E. coli
Accession:	AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGADGVGK
Molecular Weight:	The protein has a predicted MW of 35.36 kDa (HLA-A*11:01) and 11.9 kDa (B2M) same as Tris-Bis PAGE result.

**QC Testing**

Biological Activity:	Immobilized HLA-A*11:01&B2M&KRAS G12D TCR at 2µg/ml (100µl/well) on the plate. Dose response curve for Biotinylated HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer, His Tag with the EC50 of 0.1µg/ml determined by ELISA.
Purity:	> 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC
Endotoxin:	< 1.0 EU/µg of the protein as determined by the LAL method.
Formulation:	Lyophilized from a solution filtered through a 0.22 µm filter, containing PBS (pH 7.4). Typically, 8% trehalose is incorporated as a protective agent before lyophilization.

**Preparation and Storage****Reconstitution:**

Reconstitute the lyophilized protein in distilled water. The product concentration should not be less than 100 µg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing.

**Stability & Storage:**

Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

**Shipping:**

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

**Protein Background**

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic

lethality interactors of KRAS are discussed in detail.

Reference

Wu HZ, et al. KRAS: A Promising Therapeutic Target for Cancer Treatment. Curr Top Med Chem. 2019;19(23):2081-2097. doi: 10.2174/1568026619666190905164144. PMID: 31486755.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481